Clearside Biomedical to Report Second Quarter 2020 Financial Results and Provide Corporate Update on Monday, August 10, 2020

Rhea-AI Summary

Clearside Biomedical (CLSD) will report its Q2 2020 financial results on August 10, 2020, after market close. A conference call with management is set for 4:30 PM ET to discuss the results and provide updates. The company focuses on treatments targeting serious eye diseases using its proprietary SCS Microinjector®, facilitating targeted delivery of medications. This innovative technology aims to restore and preserve vision, directly addressing sight-threatening conditions.

Positive

• Anticipation of Q2 2020 financial results could stimulate investor interest.
• Innovative SCS Microinjector® technology enhances treatment delivery for serious eye diseases.

Negative

• None.

ALPHARETTA, Ga., July 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its second quarter 2020 financial results will be reported on Monday, August 10, 2020 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (844) 263-8310 (domestic) or (213) 358-0959 (international) and entering conference code: 2290836.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector^® targets the suprachoroidal space (SCS^®) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations such as gene therapy. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.

FAQ

When will Clearside Biomedical report its Q2 2020 financial results?

Clearside Biomedical will report its Q2 2020 financial results on August 10, 2020.

What is the focus of Clearside Biomedical?

Clearside Biomedical focuses on developing treatments for serious back of the eye diseases.

How can I access the Clearside Biomedical conference call?

The conference call can be accessed by dialing (844) 263-8310 for domestic calls or (213) 358-0959 for international calls, using conference code: 2290836.

What is the SCS Microinjector®?

The SCS Microinjector® is a proprietary device from Clearside Biomedical designed for targeted delivery of medications to the suprachoroidal space in the eye.